Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.

Lee DH, Jang PS, Chung NG, Cho B, Jeong DC, Kim HK.

Exp Hematol. 2013 Jun;41(6):539-46. doi: 10.1016/j.exphem.2013.02.004. Epub 2013 Feb 13.

PMID:
23415674
2.

The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.

Lui GY, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB, Richardson DR.

Mol Pharmacol. 2013 Jan;83(1):179-90. doi: 10.1124/mol.112.081893. Epub 2012 Oct 16.

3.

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.

Ford SJ, Obeidy P, Lovejoy DB, Bedford M, Nichols L, Chadwick C, Tucker O, Lui GY, Kalinowski DS, Jansson PJ, Iqbal TH, Alderson D, Richardson DR, Tselepis C.

Br J Pharmacol. 2013 Mar;168(6):1316-28. doi: 10.1111/bph.12045.

4.

Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.

Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.

Transfusion. 2014 Mar;54(3):646-9. doi: 10.1111/trf.12335. Epub 2013 Jul 9.

PMID:
23834310
5.

[Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].

Gao HY, Li Q, Chen JJ, Chen GF, Li CG.

Zhongguo Dang Dai Er Ke Za Zhi. 2011 Jul;13(7):531-4. Chinese.

6.

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.

Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

J Clin Pharm Ther. 2012 Apr;37(2):173-81. doi: 10.1111/j.1365-2710.2011.01276.x. Epub 2011 May 18.

PMID:
21592159
7.

The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.

Kim JL, Kang HN, Kang MH, Yoo YA, Kim JS, Choi CW.

Acta Haematol. 2011;126(4):241-5. doi: 10.1159/000330608. Epub 2011 Sep 27. No abstract available.

PMID:
21951998
8.

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.

Nolte F, Höchsmann B, Giagounidis A, Lübbert M, Platzbecker U, Haase D, Lück A, Gattermann N, Taupitz M, Baier M, Leismann O, Junkes A, Schumann C, Hofmann WK, Schrezenmeier H.

Ann Hematol. 2013 Jan;92(2):191-8. doi: 10.1007/s00277-012-1594-z. Epub 2012 Oct 17.

PMID:
23073603
9.

Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.

Keshtkaran A, Javanbakht M, Salavati S, Mashayekhi A, Karimi M, Nuri B.

Transfusion. 2013 Aug;53(8):1722-9. doi: 10.1111/trf.12024. Epub 2012 Dec 12.

PMID:
23241074
10.

Deferasirox.

Stumpf JL.

Am J Health Syst Pharm. 2007 Mar 15;64(6):606-16. Review.

PMID:
17353569
11.

Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programs.

Armstrong EP, Skrepnek GH, Sasane M, Snodgrass SM, Ballas SK.

J Med Econ. 2013;16(1):10-8. doi: 10.3111/13696998.2012.723081. Epub 2012 Sep 5.

PMID:
22947171
12.

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.

Ohyashiki JH, Kobayashi C, Hamamura R, Okabe S, Tauchi T, Ohyashiki K.

Cancer Sci. 2009 May;100(5):970-7. doi: 10.1111/j.1349-7006.2009.01131.x. Epub 2009 Mar 9.

13.

Bad liver and a broken heart.

Coates TD.

Blood. 2014 Mar 6;123(10):1434-6. doi: 10.1182/blood-2014-01-548552.

14.

Iron chelation in the treatment of cancer: a new role for deferasirox?

Bedford MR, Ford SJ, Horniblow RD, Iqbal TH, Tselepis C.

J Clin Pharmacol. 2013 Sep;53(9):885-91. doi: 10.1002/jcph.113. Epub 2013 Jun 6. Review.

PMID:
23740857
15.

Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.

Fischer R, Piga A, Harmatz P, Nielsen P.

Ann N Y Acad Sci. 2005;1054:350-7. Review.

PMID:
16339683
16.

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.

Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010. Review.

17.

Ascorbate status modulates reticuloendothelial iron stores and response to deferasirox iron chelation in ascorbate-deficient rats.

Brewer C, Otto-Duessel M, Lykkesfeldt J, Nick H, Wood JC.

Exp Hematol. 2012 Oct;40(10):820-7. doi: 10.1016/j.exphem.2012.06.005. Epub 2012 Jun 17.

PMID:
22713799
18.

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma.

Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I.

World J Gastroenterol. 2016 Oct 28;22(40):8967-8977.

19.

Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, Lai ME, Mangiagli A, Strauss G, Girot R, Watman N, Ferster A, Loggetto S, Abish S, Cario H, Zoumbos N, Vichinsky E, Opitz H, Ressayre-Djaffer C, Abetz L, Rofail D, Baladi JF.

Clin Ther. 2007 May;29(5):909-17.

PMID:
17697909
20.

Objectives and mechanism of iron chelation therapy.

Hershko C, Link G, Konijn AM, Cabantchik ZI.

Ann N Y Acad Sci. 2005;1054:124-35. Review.

PMID:
16339658

Supplemental Content

Support Center